一个患有结肠癌的患者中与5-fluorouracil相关的乳酸:一个病例报告
Yosuke Osawa1, Manami Kazaoka2, Takayuki Akita1
1Department of gastroenterology, International University of Health and Welfare Hospital, Japan.
Internal medicine (Tokyo, Japan)
|June 26, 2025
概括
乳酸性酸是一种罕见但严重的副作用,用于结肠癌的5-fluorouracil (5-FU) 化疗. 这一案例凸显了在接受治疗的患者中识别和管理这种不良事件的重要性.
科学领域:
- 在瘤学瘤学.
- 胃肠病学 胃肠病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 结肠癌是一种常见的恶性瘤,通常使用基于5-甲 (5-FU) 的化疗来治疗.
- 乳酸化是一种不常见但严重的不良事件,与全身5-FU暴露有关.
- 转移性结肠癌需要积极的治疗方案,增加复杂副作用的可能性.
研究的目的:
- 在接受mFOLFOX6和FOLFIRI治疗的结肠癌患者中报告一种罕见的乳酸性化病例.
- 为了突出5-FU诱导的乳酸酸的临床表现和管理.
- 在结肠癌患者接受5-FU化疗后对乳酸性化症的现有文献进行审查.
主要方法:
- 一个36岁的女性患有转移性结肠癌的病例报告.
- 使用mFOLFOX6和FOLFIRI化疗方案.
- 监测不良事件,包括代谢障碍和神经症状.
- 关于类似病例和治疗结果的文献综述.
主要成果:
- 患者在化疗后两天出现严重的乳酸性化症 (乳酸盐水平为10 mmol/L).
- 临床表现包括失去意识和.
- 用二碳酸治疗导致意识和的改善.
- 文献审查证实了这种不良事件的罕见性,但潜在的严重性.
结论:
- 系统性5-FU化疗很少会在结肠癌患者中诱导严重的乳酸性化症.
- 及时识别和支持性治疗,如二碳酸,对于管理这种并发症至关重要.
- 对于治疗结肠癌患者的瘤学家来说,意识到这种潜在的副作用很重要.
相关概念视频
01:13Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
01:31Acid Suppressive Drugs for Peptic Ulcer Disease: Antacids
In the complex environment of the gastric lumen, excessive acid secretion can lead to the formation or worsening of ulcers within the delicate mucosal layer. Antacids, such as sodium bicarbonate and calcium carbonate, provide relief by neutralizing this acid, transforming it into harmless salt and water. This neutralization process raises the gastric pH from a highly acidic level of 1 to a more basic 3-4, reducing the acidity within the stomach.
However, this neutralization reaction between...
However, this neutralization reaction between...
01:24Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
01:20Drugs Affecting GI Tract Motility: Other Laxatives
Laxatives are primarily used to alleviate constipation, a common gastrointestinal disorder characterized by infrequent bowel movements and difficulty passing stools. They work by various mechanisms to increase the volume or frequency of bowel movements. The primary modes of action of laxatives include increasing stool bulk, softening the stool, stimulating intestinal motility, and osmotically drawing water into the intestines.
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...